Pharsight

Onglyza patents expiration

ONGLYZA's oppositions filed in EPO
ONGLYZA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(a month ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7951400 ASTRAZENECA AB Coated tablet formulation and method
Nov, 2028

(5 years from now)

Onglyza is owned by Astrazeneca Ab.

Onglyza contains Saxagliptin Hydrochloride.

Onglyza has a total of 2 drug patents out of which 1 drug patent has expired.

Expired drug patents of Onglyza are:

  • USRE44186

Onglyza was authorised for market use on 31 July, 2009.

Onglyza is available in tablet;oral dosage forms.

Onglyza can be used as method for treating type ii diabetes by administering saxagliptin; method for treating type ii diabetes mellitus by administering saxagliptin alone or in combination with insulin, metformin, a thiazolidinedione, glyburide or metformin plus a sulfonylurea.

The generics of Onglyza are possible to be released after 30 November, 2028.

Drugs and Companies using SAXAGLIPTIN HYDROCHLORIDE ingredient

Market Authorisation Date: 31 July, 2009

Treatment: Method for treating type ii diabetes by administering saxagliptin; Method for treating type ii diabetes mellitus by administering saxagliptin alone or in combination with insulin, metformin, a thiazol...

Dosage: TABLET;ORAL

How can I launch a generic of ONGLYZA before it's drug patent expiration?
More Information on Dosage

ONGLYZA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic